Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients

Trial Profile

Impact of Eplerenone on Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetic Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2015

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Left ventricular dysfunction
  • Focus Therapeutic Use
  • Sponsors Solvotrin Innovations
  • Most Recent Events

    • 05 Dec 2015 Planned number of patients changed from 30 to 60, according to European Clinical Trials Database record.
    • 05 Dec 2015 Status changed from recruiting to completed, European Clinical Trials Database record.
    • 27 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top